Last reviewed · How we verify
Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors
RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.
Details
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | TERMINATED |
| Enrolment | 1 |
| Start date | 2006-10 |
| Completion | 2010-11 |
Conditions
- Brain and Central Nervous System Tumors
Interventions
- rosiglitazone maleate
Primary outcomes
- Efficacy of Rosiglitazone Maleate on Cushing Disease — 12 months
Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline.
Countries
United States